|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM185B |
Gene summary for TMEM185B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM185B | Gene ID | 79134 |
| Gene name | transmembrane protein 185B | |
| Gene Alias | FAM11B | |
| Cytomap | 2q14.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9H7F4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79134 | TMEM185B | LZE4T | Human | Esophagus | ESCC | 1.31e-03 | 1.99e-01 | 0.0811 |
| 79134 | TMEM185B | LZE20T | Human | Esophagus | ESCC | 1.29e-02 | 1.23e-01 | 0.0662 |
| 79134 | TMEM185B | LZE22T | Human | Esophagus | ESCC | 3.43e-04 | 5.10e-01 | 0.068 |
| 79134 | TMEM185B | LZE24T | Human | Esophagus | ESCC | 1.59e-13 | 3.75e-01 | 0.0596 |
| 79134 | TMEM185B | LZE21T | Human | Esophagus | ESCC | 4.78e-03 | 2.47e-01 | 0.0655 |
| 79134 | TMEM185B | P1T-E | Human | Esophagus | ESCC | 3.34e-04 | 2.96e-01 | 0.0875 |
| 79134 | TMEM185B | P2T-E | Human | Esophagus | ESCC | 8.43e-47 | 6.59e-01 | 0.1177 |
| 79134 | TMEM185B | P4T-E | Human | Esophagus | ESCC | 8.00e-33 | 8.55e-01 | 0.1323 |
| 79134 | TMEM185B | P5T-E | Human | Esophagus | ESCC | 9.94e-25 | 4.90e-01 | 0.1327 |
| 79134 | TMEM185B | P8T-E | Human | Esophagus | ESCC | 1.91e-14 | 2.07e-01 | 0.0889 |
| 79134 | TMEM185B | P9T-E | Human | Esophagus | ESCC | 2.10e-11 | 2.98e-01 | 0.1131 |
| 79134 | TMEM185B | P10T-E | Human | Esophagus | ESCC | 7.53e-28 | 6.27e-01 | 0.116 |
| 79134 | TMEM185B | P11T-E | Human | Esophagus | ESCC | 1.49e-12 | 5.89e-01 | 0.1426 |
| 79134 | TMEM185B | P12T-E | Human | Esophagus | ESCC | 1.22e-49 | 9.49e-01 | 0.1122 |
| 79134 | TMEM185B | P15T-E | Human | Esophagus | ESCC | 4.56e-27 | 6.89e-01 | 0.1149 |
| 79134 | TMEM185B | P16T-E | Human | Esophagus | ESCC | 9.91e-24 | 3.80e-01 | 0.1153 |
| 79134 | TMEM185B | P17T-E | Human | Esophagus | ESCC | 6.35e-06 | 2.32e-01 | 0.1278 |
| 79134 | TMEM185B | P20T-E | Human | Esophagus | ESCC | 3.38e-26 | 4.31e-01 | 0.1124 |
| 79134 | TMEM185B | P21T-E | Human | Esophagus | ESCC | 2.27e-30 | 6.67e-01 | 0.1617 |
| 79134 | TMEM185B | P22T-E | Human | Esophagus | ESCC | 2.85e-57 | 9.32e-01 | 0.1236 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM185B | SNV | Missense_Mutation | novel | c.214N>G | p.Arg72Gly | p.R72G | Q9H7F4 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM185B | deletion | Frame_Shift_Del | c.1022delN | p.Pro341LeufsTer4 | p.P341Lfs*4 | Q9H7F4 | protein_coding | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| TMEM185B | SNV | Missense_Mutation | c.904G>A | p.Glu302Lys | p.E302K | Q9H7F4 | protein_coding | tolerated(0.27) | benign(0.058) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD | |
| TMEM185B | deletion | Frame_Shift_Del | c.1022delN | p.Pro341LeufsTer4 | p.P341Lfs*4 | Q9H7F4 | protein_coding | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| TMEM185B | deletion | Frame_Shift_Del | c.1022delC | p.Pro341LeufsTer4 | p.P341Lfs*4 | Q9H7F4 | protein_coding | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |||
| TMEM185B | deletion | Frame_Shift_Del | c.1022delC | p.Pro341LeufsTer4 | p.P341Lfs*4 | Q9H7F4 | protein_coding | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| TMEM185B | SNV | Missense_Mutation | novel | c.134N>T | p.Ala45Val | p.A45V | Q9H7F4 | protein_coding | tolerated(1) | benign(0.009) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM185B | SNV | Missense_Mutation | novel | c.800N>A | p.Gly267Asp | p.G267D | Q9H7F4 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AX-A1C4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM185B | SNV | Missense_Mutation | novel | c.620N>A | p.Arg207Gln | p.R207Q | Q9H7F4 | protein_coding | tolerated(0.05) | probably_damaging(1) | TCGA-AX-A1C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMEM185B | SNV | Missense_Mutation | novel | c.592C>T | p.Arg198Trp | p.R198W | Q9H7F4 | protein_coding | deleterious(0.04) | probably_damaging(1) | TCGA-AX-A2HA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |